Do patients with soft-tissue sarcomas treated with trabectedin have better clinical effects and a longer survival time than those treated with doxorubicin?

Detalles Bibliográficos
Autores principales: Wu, Jiangfeng, Zhang, Maoliang, Chen, Chunting, Zhao, Anli, Guo, Yinghong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2022
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9073773/
https://www.ncbi.nlm.nih.gov/pubmed/35530946
http://dx.doi.org/10.21037/atm-21-7018

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9073773/
https://www.ncbi.nlm.nih.gov/pubmed/35530946
http://dx.doi.org/10.21037/atm-21-7018

Ejemplares similares